|
US20030044384A1
(en)
*
|
1997-10-09 |
2003-03-06 |
Pro-Virus, Inc. |
Treatment of neoplasms with viruses
|
|
CA2388807C
(en)
|
1999-11-12 |
2013-08-06 |
Matthew C. Coffey |
Viruses for the treatment of cellular proliferative disorders
|
|
AUPQ425699A0
(en)
|
1999-11-25 |
1999-12-23 |
University Of Newcastle Research Associates Limited, The |
A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
|
|
WO2001041801A2
(en)
*
|
1999-12-08 |
2001-06-14 |
Onyx Pharmaceuticals, Inc. |
Mutant simplex virus for treating unwanted hyperproliferative cell growth
|
|
US8491884B2
(en)
|
2000-05-03 |
2013-07-23 |
Oncolytics Biotech Inc. |
Virus clearance of neoplastic cells from mixed cellular compositions
|
|
AR028040A1
(es)
*
|
2000-05-03 |
2003-04-23 |
Oncolytics Biotech Inc |
Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas
|
|
AR028039A1
(es)
|
2000-05-03 |
2003-04-23 |
Oncolytics Biotech Inc |
Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
|
|
US7306902B2
(en)
*
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
|
US20050013803A1
(en)
*
|
2000-07-07 |
2005-01-20 |
Benjamin Thomas L. |
Diagnosing and treating cancer cells using mutant viruses
|
|
US20020147996A1
(en)
*
|
2000-07-07 |
2002-10-10 |
Benjamin Thomas L. |
Diagnosing and treating cancer cells using Sal2
|
|
US20020156039A1
(en)
*
|
2000-07-07 |
2002-10-24 |
Benjamin Thomas L. |
Diagnosing and treating cancer cells using Sal2
|
|
US20030157481A1
(en)
*
|
2001-12-10 |
2003-08-21 |
Benjamin Thomas L. |
Diagnosing and treating cancer cells using T-HR mutants and their targets
|
|
US6982251B2
(en)
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
|
US7071181B2
(en)
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
|
CA2434430A1
(en)
|
2001-01-26 |
2002-08-01 |
Harry R. Davis |
The use of substituted azetidinone compounds for the treatment of sitosterolemia
|
|
ES2274013T3
(es)
|
2001-01-26 |
2007-05-16 |
Schering Corporation |
Combinaciones de activador(es) del receptor activado por el proliferador de los peroxisomas (ppar) e inhibidor(es)m de la absorcion de estelores y tratamientos para trastornos vasculares.
|
|
AR035227A1
(es)
*
|
2001-02-20 |
2004-05-05 |
Oncolytics Biotech Inc |
Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
|
|
US7056906B2
(en)
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
|
US7053080B2
(en)
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
|
AU2002336609B2
(en)
|
2001-09-21 |
2006-08-24 |
Merck Sharp & Dohme Corp. |
Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
|
|
EP1499355A4
(en)
*
|
2001-12-07 |
2005-10-05 |
Bayer Pharmaceuticals Corp |
USE OF PARAPOX B2L PROTEIN FOR THE TREATMENT OF CANCER AND THE MODIFICATION OF IMMUNE RESPONSES
|
|
JP2005526099A
(ja)
*
|
2002-03-26 |
2005-09-02 |
オンコリティクス バイオテック， インコーポレイティッド |
癌治療のための、ｖａ遺伝子が変異したアデノウイルスの使用
|
|
US20040180438A1
(en)
*
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
|
WO2003090676A2
(en)
*
|
2002-04-26 |
2003-11-06 |
Wellstat Biologics Corporation |
Immunogenic agent therapy using plasmapheresis or exchange transfusion
|
|
WO2004009763A2
(en)
|
2002-07-24 |
2004-01-29 |
Arizona Board Of Regents |
Use of vaccinia virus deleted for the e3l gene as a vaccine vector
|
|
CN1754002B
(zh)
|
2002-08-12 |
2010-09-08 |
杰能斯有限公司 |
涉及痘病毒和癌的组合物及制备方法
|
|
WO2004043457A1
(en)
|
2002-11-06 |
2004-05-27 |
Schering Corporation |
Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
|
|
AU2002953436A0
(en)
|
2002-12-18 |
2003-01-09 |
The University Of Newcastle Research Associates Limited |
A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
|
|
WO2004081004A1
(en)
|
2003-03-07 |
2004-09-23 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
|
CN1756756A
(zh)
|
2003-03-07 |
2006-04-05 |
先灵公司 |
取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
|
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
|
US7235543B2
(en)
|
2003-03-07 |
2007-06-26 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
|
BRPI0411526A
(pt)
|
2003-06-18 |
2006-08-01 |
Genelux Corp |
vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos
|
|
US20070036758A1
(en)
*
|
2003-07-08 |
2007-02-15 |
Bertram Jacobs |
Mutants of vaccinia virus as oncolytic agents
|
|
US7442372B2
(en)
|
2003-08-29 |
2008-10-28 |
Biomarin Pharmaceutical Inc. |
Delivery of therapeutic compounds to the brain and other tissues
|
|
WO2006031996A2
(en)
*
|
2004-09-14 |
2006-03-23 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Targeting viruses using a modified sindbis glycoprotein
|
|
US20060160837A1
(en)
*
|
2004-12-29 |
2006-07-20 |
The Brigham And Women's Hospital, Inc. |
Rapamycin compounds in the treatment of neurofibromatosis type 1
|
|
HUE030037T2
(en)
|
2005-02-23 |
2017-04-28 |
Bavarian Nordic As |
Use of modified anemic virus for rapid induction of immunity against gluten virus or other agents
|
|
NZ560840A
(en)
*
|
2005-03-07 |
2009-07-31 |
Robarts Res Inst |
Use of a combination of myxoma virus and rapamycin for therapeutic treatment
|
|
US20070004767A1
(en)
*
|
2005-06-30 |
2007-01-04 |
Gutmann David H |
Methods for treating neurofibromatosis 1
|
|
US10668119B2
(en)
|
2005-08-01 |
2020-06-02 |
Virocure, Inc. |
Attenuated reovirus
|
|
EP1917351A4
(en)
|
2005-08-01 |
2009-12-16 |
Univ Technologies Int |
ATTENUATED REOVIRUS
|
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
|
AU2006287441B2
(en)
|
2005-09-07 |
2012-09-06 |
Sillajen Biotherapeutics, Inc. |
Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses
|
|
WO2007093036A1
(en)
*
|
2006-02-13 |
2007-08-23 |
Oncolytics Biotech Inc. |
Use of local immune suppression to enhance oncolytic viral therapy
|
|
US8052968B2
(en)
*
|
2006-10-16 |
2011-11-08 |
Genelux Corporation |
Modified vaccinia virus strains for use in diagnostic and therapeutic methods
|
|
US10369171B2
(en)
|
2007-03-13 |
2019-08-06 |
Virocure, Inc. |
Attenuated reoviruses for selection of cell populations
|
|
WO2008156655A2
(en)
|
2007-06-15 |
2008-12-24 |
Genelux Corporation |
Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
|
|
CA2693623A1
(en)
*
|
2007-07-18 |
2009-01-22 |
Genelux Corporation |
Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
|
|
WO2009135614A2
(en)
*
|
2008-05-09 |
2009-11-12 |
Bayer Schering Pharma Aktiengesellschaft |
Use of a virus regimen for the treatment of diseases
|
|
EP2300023A2
(en)
*
|
2008-05-16 |
2011-03-30 |
Genelux Corporation |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
CA2723580A1
(en)
*
|
2008-05-27 |
2009-12-03 |
Oncolytics Biotech Inc. |
Modulating interstitial pressure and oncolytic viral delivery and distribution
|
|
CN102292078A
(zh)
|
2008-11-11 |
2011-12-21 |
得克萨斯大学体系董事会 |
哺乳动物雷帕霉素靶蛋白的抑制
|
|
HUE038708T2
(hu)
|
2009-09-14 |
2018-11-28 |
Sillajen Biotherapeutics Inc |
Onkolitikus vaccinia vírus kombinációs rákterápia
|
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
|
US9919047B2
(en)
|
2011-01-04 |
2018-03-20 |
Sillajen, Inc. |
Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
|
|
WO2012122649A1
(en)
*
|
2011-03-15 |
2012-09-20 |
Ottawa Hospital Research Institute |
Recombinant orf virus
|
|
CN114262690A
(zh)
|
2011-04-15 |
2022-04-01 |
吉恩勒克斯公司 |
减毒的痘苗病毒的克隆毒株及其使用方法
|
|
EP2764119A2
(en)
|
2011-10-05 |
2014-08-13 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
|
DK2968281T3
(da)
|
2013-03-13 |
2020-11-02 |
Univ Texas |
Mtor-hæmmere til forebyggelse af vækst af tarmpolyp
|
|
CA2903582C
(en)
|
2013-03-14 |
2021-06-08 |
Salk Institute For Biological Studies |
Oncolytic adenovirus compositions
|
|
DE102013105144A1
(de)
*
|
2013-05-17 |
2014-11-20 |
Arno Thaller |
Pharmazeutisches Kombinationspräparat mit einem anti-idiotypischen Antikörperfragment
|
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
|
CA2933908C
(en)
|
2013-12-31 |
2024-01-30 |
Rapamycin Holdings, Llc |
Oral rapamycin nanoparticle preparations and use
|
|
ES2841075T3
(es)
|
2014-10-24 |
2021-07-07 |
Calidi Biotherapeutics Inc |
Enfoque de inmunoterapia de combinación para el tratamiento del cáncer
|
|
EP3261669B1
(en)
|
2015-02-25 |
2022-08-03 |
Memorial Sloan Kettering Cancer Center |
Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
|
|
US10548930B2
(en)
|
2015-04-17 |
2020-02-04 |
Memorial Sloan Kettering Cancer Center |
Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
|
|
JP6788663B2
(ja)
|
2015-08-11 |
2020-11-25 |
カリディ・バイオセラピューティクス・インコーポレイテッドＣａｌｉｄｉ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
癌処置のための天然痘ワクチン
|
|
CN109312309B
(zh)
|
2016-01-08 |
2024-04-02 |
雷普利穆内有限公司 |
工程化的病毒
|
|
CN105754952B
(zh)
*
|
2016-02-16 |
2020-07-10 |
中国农业科学院兰州兽医研究所 |
抗羊痘病毒k3l蛋白c末端的单克隆抗体及其应用
|
|
WO2017147265A1
(en)
|
2016-02-23 |
2017-08-31 |
Salk Institute For Biological Studies |
High throughput assay for measuring adenovirus replication kinetics
|
|
JP7015551B2
(ja)
|
2016-02-23 |
2022-02-15 |
ソーク インスティテュート フォー バイオロジカル スタディーズ |
ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
|
|
IL261321B2
(en)
|
2016-02-25 |
2023-12-01 |
Memorial Sloan Kettering Cancer Center |
Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors
|
|
WO2017147553A2
(en)
|
2016-02-25 |
2017-08-31 |
Memorial Sloan-Kettering Cancer Center |
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
|
|
CA3057579A1
(en)
*
|
2016-03-25 |
2017-09-28 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Synthetically enveloped virus
|
|
WO2017205674A1
(en)
*
|
2016-05-25 |
2017-11-30 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Oncolytic vaccinia virus mutants and using same for cancer treatment
|
|
EP3489354B1
(en)
*
|
2016-07-21 |
2024-03-27 |
Kolon Life Science, Inc. |
Recombinant vaccinia virus and use thereof
|
|
CA3045892A1
(en)
|
2016-12-12 |
2018-06-21 |
Salk Institute For Biological Studies |
Tumor-targeting synthetic adenoviruses and uses thereof
|
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
|
CN111107872A
(zh)
|
2017-05-12 |
2020-05-05 |
纪念斯隆-凯特林癌症中心 |
有用于癌症免疫疗法的牛痘病毒突变体
|
|
US10610583B2
(en)
|
2017-08-31 |
2020-04-07 |
Regents Of The University Of Minnesota |
Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus
|
|
US20220347244A1
(en)
*
|
2018-01-19 |
2022-11-03 |
Kolon Life Science, Inc. |
Recombinant vaccinia virus and pharmaceutical composition comprising same
|
|
AU2019251356B2
(en)
|
2018-04-09 |
2025-06-12 |
Salk Institute For Biological Studies |
Oncolytic adenovirus compositions with enhanced replication properties
|
|
US11505782B2
(en)
|
2018-06-04 |
2022-11-22 |
Calidi Biotherapeutics, Inc. |
Cell-based vehicles for potentiation of viral therapy
|
|
AU2019339535B2
(en)
|
2018-09-15 |
2025-11-20 |
Memorial Sloan Kettering Cancer Center |
Recombinant poxviruses for cancer immunotherapy
|
|
US20220362316A1
(en)
*
|
2019-08-26 |
2022-11-17 |
Bionoxx Inc. |
Pharmaceutical composition for treating cancer comprising anticancer virus, immune checkpoint inhibitor and hydroxyurea as active ingredients
|